FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA)

Affiliation auteurs!!!! Error affiliation !!!!
TitreFOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA)
Type de publicationJournal Article
Year of Publication2015
AuteursMalka D, Castan F, Francois E, Bouche O, Bennouna J, Ghiringhelli F, de la Fouchardiere C, Borg C, Samalin E, Bachet JBaptiste, Raoul J-L, Cvitkovic F, Miglianico L, Bengrine-Lefevre L, Dahan L, Lecaille C, Aparicio T, Perrier H, Gourgou S, Taieb J, AGEO
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.15_suppl.4013